Voriconazole therapeutic drug monitoring including analysis of CYP2C19 phenotype in immunocompromised pediatric patients with invasive fungal infections
The C<sub>trough</sub> of VCZ is characterized by inter-individual variability and a low rate of patients reaching the therapeutic range. The significant association exists in children between VCZ C<sub>trough</sub> and CYPC19 phenotype. The combination of repeated TDM and genotyping is necessary to ensure effective treatment.
Authors
- Franciszek K. Główka (ORCID: https://orcid.org/0000-0002-6611-5789)
- Agnieszka Sobkowiak-Sobierajska (ORCID: https://orcid.org/0000-0002-5237-6646)
- Matylda Resztak (ORCID: https://orcid.org/0000-0002-5495-8594)
- Paulina Zalewska
- Jacek Wachowiak (ORCID: https://orcid.org/0000-0002-4680-603X)
Institutions
- Poznan University of Medical Sciences (PL)
Publication Details
- Journal
- European Journal of Clinical Pharmacology
- Published
- 2024-09-06
- DOI
- https://doi.org/10.1007/s00228-024-03752-z
- Citations
- 6
- Primary Topic
- Antifungal resistance and susceptibility
- Type
- article
- Field-Weighted Citation Impact
- 2.33